-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
SUZHOU, Aug.
This Phase I clinical trial in China is a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of single and multiple topical administration of GT20029 (gel/tincture) in healthy subjects.
Preclinical studies have shown that GT20029 can effectively block the AR signaling pathway and its physiological function by degrading AR protein.
Dr.
About GT20029
GT20029 is a topical compound developed by Kintor Pharmaceuticals based on PROTAC technology.
Source: Kintor Pharmaceuticals